46 results about "Left ventricular ejection" patented technology

The invention provides a left heart data analysis method and system based on image segmentation, and relates to the technical field of medical image processing. Comprising the following steps: acquiring cardiac ultrasound image data and preprocessing; performing image segmentation on the preprocessed image data to obtain a segmentation result including a left ventricle, a left ventricular wall and a left atrium; searching a boundary line of the left ventricle and the left atrium, selecting two boundary points corresponding to the minimum and maximum abscissas in the boundary line as left and right mitral valve ring points respectively, and establishing a long axis based on the mitral valve ring midpoint and the cardiac apex point; modeling the ventricle into a structure formed by superposing a plurality of discs along the long axis direction, and obtaining the diameter of the corresponding disc; based on the obtained diameters of the corresponding discs, the left ventricular volumes in the diastolic period and the systolic period are calculated respectively, and the left ventricular ejection fraction is calculated. According to the method, image segmentation and geometric modeling are fused to achieve accurate calculation of the cardiac ejection fraction, meanwhile, the accuracy of cardiac structure image segmentation is improved, and an interpretable ejection fraction estimation process is achieved.

The invention provides application of a monascus composition in preparation of a medicine for preventing and / or treating coronary microcirculation disturbance. The monascus composition comprises one or more of cortex mori, ramulus mori and folium mori, monascus and radix puerariae. When the composition containing the red yeast rice is applied to preparation of the medicine for preventing and / or controlling coronary microcirculation disturbance, the abnormal microvascular structure can be improved (myocardial microvascular density MVD is increased, edema around microvessels is relieved, the lumen stenosis phenomenon is improved, and the endothelial cell condition is good); 2) microvascular occlusion is improved (pathologic results show that microvascular contents are reduced); (3) the abnormal vasodilatation and contraction function of the microvessels is improved (NO is increased); 4) improving blood lipid metabolism disorder; and (5) the heart function is improved (the left ventricular ejection fraction LVEF and the left ventricular short axis shortening rate LVFS are improved, and the left ventricular pressure maximum rising rate LV + dp / dtmax and the left ventricular pressure maximum falling rate LV-dp / dtmax are increased).

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-propionic acid in preparation of a medicine for treating myocardial ischemia-reperfusion injury. A stable and reliable mouse MIRI model is successfully constructed through a coronary artery ligation left anterior descending branch reperfusion method, and it is found through indole-3-propionic acid (IPA) intervention and multi-dimensional evaluation that IPA administration can significantly improve the left ventricular ejection fraction LVEF and the left ventricular short-axis shortening rate LVFS of a model mouse, reduce the left ventricular end diastolic inner diameter LVEDd and the end systolic inner diameter LVESd, and significantly improve the model mouse left ventricular ejection fraction LVEF, the left ventricular end diastolic inner diameter LVEDd and the left ventricular end diastolic inner diameter LVESd. The heart function is effectively improved; the myocardial fibrosis area can be reduced, the mRNA expression of fibrosis-promoting and pathological hypertrophy-promoting molecules in myocardial tissues can be obviously reduced, and the myocardial injury progress can be inhibited in a multi-dimensional manner. The invention provides a brand new strategy for treating myocardial ischemia reperfusion injury, has important application value and wide clinical transformation prospect, and is expected to provide a new direction for clinical treatment.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

The invention discloses a motion intervention heart failure repair method based on Lgmn signal regulation and control, and relates to the technical field of heart failure treatment. According to the method, through aerobic exercise training (AET) with specific parameters, expression of Legumain (Lgmn) genes in macrophages is regulated in a targeted mode, the interburial effect of the macrophages is enhanced, then cell communication between the macrophages and cardiac muscle cells is enhanced, removal of the vertical death cardiac muscle cells is promoted, myocardial fibrosis and inflammatory response are relieved, and the effect of treating myocardial fibrosis is achieved. Finally, ventricular remodeling and heart functions of chronic heart failure (CHF) mice are improved. Experimental verification shows that the exercise intervention method can significantly improve the left ventricular ejection fraction (LVEF) and shortening fraction (FS) of CHF model animals, reduce the left ventricular end-of-systole inner diameter (LVESD), reduce myocardial cell apoptosis and necrosis, and promote inflammation regression. Drug intervention is not needed, safety is high, operation is easy and convenient, and a new effective way is provided for clinical rehabilitation treatment of heart failure.

The traditional Chinese medicine composition is characterized by being prepared from the following traditional Chinese medicinal materials in parts by weight: 3 to 9 parts of rhizoma chuanxiong, 3 to 7 parts of rhizoma atractylodis, 6 to 14 parts of rhizoma cyperi, 6 to 14 parts of medicated leaven, 3 to 7 parts of euphorbia helioscopia, 10 to 20 parts of poria cocos, 8 to 12 parts of fructus trichosanthis, 8 to 12 parts of radix salviae miltiorrhizae, 8 to 12 parts of herba epimedii, 3 to 9 parts of pepper, 8 to 12 parts of herba patriniae and 8 to 12 parts of caulis spatholobi. After the traditional Chinese medicine composition is used for treating acute myocardial infarction, a remarkable effect is achieved on PCI postoperative improvement of acute myocardial infarction, troponin and creatine kinase isoenzyme indexes are reduced, and the left ventricular ejection fraction is in a normal range after cardiac color ultrasound display treatment. Through comprehensive conditioning, symptoms such as chest distress, chest pain, shortness of breath and hypodynamia of patients are improved, cardiac function recovery is promoted, complications such as restenosis and heart failure are prevented, and life quality is improved.

Described herein is an apparatus and a method for left ventricular ejection fraction (LVEF) prediction. An apparatus may include at least a processor, and a memory communicatively connected to the at least processor, wherein the memory contains instructions configuring the at least processor to receive a first electrocardiogram (ECG) datum; input the first ECG datum into an LVEF prediction model; and receive as an output from the LVEF prediction model a first LVEF prediction.

The invention provides a method for measuring the left ventricular ejection fraction of a dynamic echocardiography. The method comprises the following steps: inputting a to-be-identified echocardiogram sequence into a neural network segmentation model based on multi-frame feature aggregation, then performing spatial feature coding on each frame of image of the to-be-identified echocardiogram sequence through a spatial feature encoder structure to obtain a spatial feature map corresponding to each frame of image, and finally, identifying the to-be-identified echocardiogram sequence according to the spatial feature map. Performing cross-frame and cross-section spatio-temporal feature aggregation on the spatial feature pattern through a spatio-temporal feature aggregation structure to obtain global spatio-temporal features including time sequence information of a heart apex two-cavity section and a heart apex four-cavity section; the left ventricular ejection fraction determining method comprises the steps of generating a left ventricular membrane segmentation mask of a terminal diastole frame and a terminal systole frame on the basis of global spatial-temporal characteristics and spatial shallow layer characteristics corresponding to the terminal diastole frame and the terminal systole frame, and finally determining the left ventricular ejection fraction on the basis of the left ventricular membrane segmentation mask of the terminal diastole frame and the terminal systole frame.

According to the left ventricular ejection fraction continuous prediction method based on the II-lead electrocardiogram, continuous regression prediction from single-lead electrocardiosignals to EF numerical values is achieved by constructing a deep neural network model fusing a convolutional neural network (CNN) and a long-short-term memory network (LSTM), and the method has the advantages of being easy and convenient to collect, accurate in prediction and flexible in deployment and has good application prospects. The continuous non-invasive prediction of the EF can be realized, the dependence on equipment, artificial experience and operation environment in the prior art is overcome, and a brand new solution is provided for bedside dynamic cardiac function monitoring. And the method has remarkable medical practical value and industrial transformation prospect.

The invention discloses a left ventricular ejection fraction regression prediction system based on transfer learning and multi-view fusion, and belongs to the field of medical image analysis. The problem that an existing deep learning method is poor in left ventricular ejection fraction prediction accuracy is solved. According to the method, the A4C view angle echocardiogram data and the PSAX view angle echocardiogram data are subjected to independent model pre-training, and then the pre-trained model parameters are subjected to transfer learning, so that a better initialization effect can be obtained, and model convergence and performance optimization are accelerated. The double-view-angle fusion regression module can well combine spatial and temporal features output by the two single-view-angle models, feature relevance of echocardiogram data of the two view angles is greatly utilized, and the accuracy of final model prediction can be improved. In addition, through fusion of the multi-view echocardiogram data features, the influence of anatomical structure differences on the detection result is effectively reduced. The method can be applied to left ventricular ejection fraction regression prediction.

The invention discloses a method for predicting heart failure based on left ventricular ejection fraction, which develops and trains a primitive model to automatically provide help and evaluate the level of clinical decision based on LVEF heart failure. The training model is prevented from using any or biased clinical variables, and the following two steps are ensured: investigating the statistical significance of each variable to distinguish the three categories; secondly, a novel dimension reduction technology is adopted to visually observe the characterization of the optimal variable in the radial direction, and each LVEF-based HF category is separated; and on the basis, the performance of the developed model is trained, the importance of the most important clinical variables is discussed, and the significance of the clinical variables is explained in detail based on the application of LVEF-based deep learning in HF analysis, so that patient data of three heart failure types are distinguished.

The invention belongs to the field of new application of medicines, and particularly relates to application of Oloinab in preparation of medicines for treating and / or preventing ischemic cardiomyopathy. Animal experiments prove that Oloinab can remarkably improve the left ventricular ejection fraction and the left ventricular short axis shortening rate of myocardial infarction model mice, improve the heart function and reduce the cardiac fibrosis area, and it is indicated that Oloinab has the effect of improving myocardial remodeling and systolic dysfunction. The discovery provides a new treatment strategy for ischemic cardiomyopathy, and has an important clinical application prospect.

This application provides an ultrasound cardiac dynamic monitoring system and method, relating to the field of ultrasound cardiac function dynamic monitoring technology. The system includes: a patch-type ultrasound probe, a hydrogel patch, a wearable hardware module, and a cardiac function analysis module. The cardiac function analysis module is configured to: receive the ultrasound image; determine a target sampling line in the ultrasound image based on a reinforcement learning model; control the wearable hardware module to acquire M-mode images along the target sampling line; input the M-mode images into a deep learning model to output the key point positions of the left ventricular septum and the left ventricular posterior wall at end-diastole and end-systole based on the deep learning model; calculate the left ventricular ejection fraction (LVEF) based on the LVEF and the key point positions; the LVEF represents the dynamic monitoring and detection results of cardiac function. This system can improve the effectiveness and accuracy of dynamic cardiac monitoring.

The present invention discloses a traditional Chinese medicine preparation for preventing and / or treating myocardial infarction, its preparation method and application, belonging to the technical field of pharmaceuticals. The traditional Chinese medicine is obtained by extracting Areca catechu with 20% - 95% ethanol. The present invention first reveals that the Areca catechu extract has an anti-myocardial infarction effect. The experimental results show that the crude extract of Areca catechu can significantly inhibit H2O2-induced cardiomyocyte death, improve the left ventricular ejection fraction of myocardial infarction mice, and reduce the myocardial infarction area, and the effect is equivalent to that of the positive drug Suxiao Jiuxin Pills, while arecoline has no cardiomyocyte protection effect. The present invention is of natural origin, simple to prepare, and low in cost, and can be used as a new supplement or alternative for clinical prevention and treatment of myocardial infarction, and has important clinical value and application prospects.

Embodiments of the present disclosure provide a left ventricular ejection fraction prediction method, device, equipment, medium and product. The method comprises: acquiring a heart ultrasound sequence of a heart part; inputting the heart ultrasound sequence into a target processing model trained in advance to output a left ventricular graph sequence which has been marked with a left ventricle; determining a plurality of effective image pairs according to area change rates of a plurality of left ventricular segmentation images in the left ventricular graph sequence, and determining left ventricular end-diastolic volumes and left ventricular end-systolic volumes corresponding to each effective image pair; and determining a left ventricular ejection fraction according to the left ventricular end-diastolic volumes and the left ventricular end-systolic volumes associated with the plurality of effective image pairs. The technical solution of the embodiments of the present disclosure processes the heart ultrasound sequence based on the target processing model to determine the left ventricular ejection fraction, which can weaken the influence of factors such as poor single-frame quality, respiratory jitter and arrhythmia, thereby achieving the effect of improving the accuracy of the left ventricular ejection fraction.

The application discloses a new application of 3-HPPA in preparing a drug for treating myocardial infarction. By means of modern pharmacological research methods, it is first confirmed that 3-HPPA has a significant myocardial protective effect. Experimental research shows that 3-HPPA can significantly improve the heart function of a myocardial infarction mouse induced by coronary artery ligation, improve the left ventricular ejection fraction and the short axis shortening rate, and reduce the infarction area; meanwhile, 3-HPPA can significantly inhibit the gene expression of a heart failure marker BNP, and down-regulate the expression levels of inflammatory factors IL-6, TNF-alpha and fibrosis related factors TGF-beta and Collagen I. Further mechanism research shows that 3-HPPA also plays an anti-inflammatory, anti-fibrosis and anti-apoptosis role. The application discloses the action characteristics of 3-HPPA in multi-target intervention of the pathological process of myocardial infarction, provides an important candidate compound for development of a new type of anti-myocardial infarction drug, and has a wide clinical application prospect.

The invention belongs to the field of biological materials and cardiovascular repair, and relates to hydrogel for repairing after myocardial infarction as well as a preparation method and application of the hydrogel. The hydrogel consists of chitosan or a derivative thereof, silk fibroin, tannic acid and a biological cross-linking agent in a weight ratio of 3: (0.8-1.2): (0.1-3.0): (0.1-0.2). According to the invention, tannic acid is introduced into the chitosan-silk fibroin composite hydrogel as a cross-linking agent and a rigidity reinforcing agent, so that the compressive strength of the hydrogel is increased from 34.4 kPa to 84.45 kPa, and the elastic modulus is increased to gt; and the mechanical property of the material is matched with that of the myocardial tissue. Meanwhile, the hydrogel can realize multi-dimensional coordinated regulation and control on oxidative stress, inflammatory response and myocardial fibrosis: in a myocardial infarction model, the hydrogel enables the left ventricular ejection fraction (LVEF) to be increased by 25%, the active oxygen clearance rate to be increased by 45%, the inflammatory cell infiltration to be reduced by 45%, the proinflammatory cytokine (IL-6 / TNF-alpha) level to be reduced by 30%, and the fibrosis area to be reduced by 40%; therefore, the heart failure process after myocardial infarction is effectively delayed.

The invention discloses a main artery elastic reservoir simulation device, and relates to the technical field of medical teaching equipment. The device comprises a simulation left ventricle unit and a simulation right ventricle unit, wherein the simulation left ventricle unit is composed of a balloon capable of absorbing water and compressing and jetting water; the interior of the auxiliary part is composed of an adjusting pipe; and the simulated aorta unit is a main pipeline, and one end of the main pipeline is connected with the right side of the auxiliary component. Compared with the prior art, the device has the advantages that by simulating the processes of left ventricular ejection and main artery elastic retraction and comparing the elastic hose and the non-elastic hard tube, the action mechanism of the main artery blood vessel elastic storage device in the heart ejection process can be visually and vividly displayed, the abstract physiological process is converted into visual demonstration, and the demonstration efficiency is improved. And students are helped to understand related knowledge of blood circulation in cardiac physiology.

The invention provides application of gamma-linolenic acid in preparation of a medicine for preventing or treating diabetic cardiomyopathy. In-vivo and in-vitro experimental results show that the gamma-linolenic acid has a better effect in diabetic cardiomyopathy, which is mainly reflected in reducing oxidative stress (reducing lipid peroxidation), increasing expression of GSH and HO-1, reducing expression of MDA and Nrf2, increasing left ventricular ejection fraction (LVEF) and shortening fraction (FS), and repairing myocardial interstitial fibrosis. Therefore, the gamma-linolenic acid has the potential of being developed into the medicine for treating the diabetic cardiomyopathy.

The invention relates to a left ventricular mass correction ejection fraction prediction risk system, which comprises a data acquisition module used for acquiring the measurement data of the left ventricular ejection fraction and the left ventricular mass of a patient; the correction calculation module is in communication connection with the data acquisition module and is used for calculating a correction parameter based on the left ventricle quality according to the measurement data; the risk assessment module is connected with the correction calculation module and used for constructing a risk assessment model based on the correction parameters and the clinical covariables and outputting an individualized risk layering result, and the correction calculation module can analyze and establish a relation model of the correction parameters and the cardiac event risks through a restrictive cubic spline and output the individualized risk layering result. Comprising the steps that data standardization processing is carried out on correction parameters, segmentation fitting is carried out based on preset spline nodes, fitting curve coefficients are solved through a least square method to form a nonlinear relation curve, the model goodness of fit is evaluated through statistical test, and the correction parameters comprise one or more of LVEF / LVM, LVEF / LVM / BSA and LVEF / LVM / BMI.

The invention discloses application of Eraffibulaol in preparation of a medicine for treating myocardial remodeling of diabetic cardiomyopathy, and belongs to the technical field of medicines. By researching the influence of the Eraffibularox on diabetic cardiomyopathy-induced myocardial remodeling model mice, it is confirmed that the Eraffibularox can relieve myocardial remodeling, and heart functions such as left ventricular ejection fraction and the like are reversed and improved at first; secondly, the pathological staining cardiac hypertrophy and fibrosis level is reduced, and the marker level is reduced; finally, it is found that the traditional Chinese medicine composition has an obvious improvement effect on glucose and lipid metabolism disorder in reconstructed heart tissue. The invention provides a novel application of Eraffibulanol in preparation of a medicine for treating myocardial remodeling of diabetic cardiomyopathy, and provides more treatment strategies for clinical treatment of diabetic cardiomyopathy.

The invention relates to a stem cell miRNA modification and targeted delivery method based on space transcriptomics and application. The method comprises the following steps: screening high-expression miR-21 and miR-126 in a wound proliferation region by integrating Vision and Stereo-seq technologies; by adopting optimized liposome transfection and electroporation methods, the expression quantity of miR-21 is increased by 12.5 times, the expression quantity of miR-126 is increased by 15.7 times, and the cell activity is maintained at 90% or above. The surface of the hyaluronic acid nano-carrier with the particle size of 200-300 nanometers is used for modifying CD11b and ICAM-1 antibodies, so that accurate delivery is realized, and the stem cell migration capability is improved by 92%. In a rat skin wound model, the 7-day healing rate of an experimental group reaches 85.0 + / -3.2% which is obviously higher than 62.0 + / -4.5% of a control group; in a myocardial infarction model, the left ventricular ejection fraction of an experimental group is increased to 48.3 + / -5.2% which is obviously superior to 28.7 + / -4.1% of a model group, and meanwhile, the inflammatory factor level is reduced by 76% to 82%. The method provides an efficient and safe treatment strategy for tissue wound repair.

The invention relates to the technical field of biological medicines, in particular to application of indole-3-lactic acid in preparation of a medicine for treating heart failure. The application potential of indole-3-lactic acid (ILA) in treatment of ejection fraction retention type heart failure (HFpEF) is proposed and verified for the first time. By constructing a mouse HFpEF model, researches prove that ILA can significantly improve the diastolic function of the heart, specifically, the E / E'ratio is significantly reduced, and meanwhile, the left ventricular ejection fraction and the short-axis shortening rate are not affected, which indicates that the ILA effectively relieves the core pathological feature-diastolic dysfunction of the HFpEF on the basis of maintaining the systolic function of the heart.

The invention provides a construction method of a mouse heart failure model based on NCL gene myocardial specific knockout induction and application of NCL gene myocardial knockout. According to the method, Nclflox / flox and Myh6-Cre mice of 5-6 weeks old are used, NCL genes in cardiac muscle cells of the mice are specifically knocked out, the mice are continuously fed until the ejection fraction of a left ventricle is smaller than 50%, and the adult mouse heart failure model based on cardiac muscle cell nucleolin specific knockout is obtained. The successful construction of the model provides a key technical support for exploring heart diseases mediated by nucleolin-related pathways in myocardial cells, effectively fills the blank of demands of the research field in the aspect of experimental vectors, and has indispensable important significance for promoting heart disease mechanism research and transforming medical development.

Introduced here approaches to developing, training, and implementing algorithms to cardiac dysfunction through automated analysis of physiological data. As an example, a model may be developed and then trained to quantify left and right ventricular dysfunction using electrocardiogram waveform data that is associated with a population of individuals who are diverse in terms of age, gender, ethnicity, socioeconomic status, and the like. This approach to training allows the model to predict the presence of left and right ventricular dysfunction in a diverse population. Also introduced here is a regression framework for predicting numeric values of left ventricular ejection fraction.

The invention provides an application of a Wnt / beta-catenin inhibitor in preparation of a medicine for treating myocardial infarction, and belongs to the technical field of biological medicines. And the Wnt / beta-catenin inhibitor is KYA1797K, and the Wnt / beta-catenin inhibitor is KYA1797K According to the application disclosed by the invention, the expression of beta-catenin protein is successfully inhibited through a KYA1797K targeted Wnt / beta-catenin pathway, the cardiac function of a myocardial infarction mouse is remarkably improved, and the left ventricular ejection fraction (EF) and the left ventricular shortening fraction (FS) are remarkably recovered, so that the Wnt / beta-catenin inhibitor KYA1797K has a good treatment effect on myocardial infarction. In addition, a myocardial fibrosis area of a KYA1797K treatment group is obviously reduced, which indicates that the KYA1797K has an anti-myocardial fibrosis effect. The development result further proves the potential application value in myocardial infarction treatment.

The invention provides a deep learning-based method for automatically quantifying a left ventricular ejection fraction of an echocardiogram. Comprising the steps that an echocardiogram is obtained, and the echocardiogram comprises a cardiac apex four-cavity cardiac tangent plane A4C, a cardiac apex two-cavity cardiac tangent plane A2C and a cardiac apex three-cavity cardiac tangent plane A3C; determining a left ventricular region image of the echocardiogram; based on a left ventricle segmentation and key point detection method, determining a target image corresponding to the left ventricle region image; performing segmentation operation on the target image to obtain a left ventricle segmentation mask; performing key positioning operation on the target image to obtain key point position information of a left target image; the ejection fraction is determined based on the left ventricular segmentation mask and the keypoint location information. According to the method, a single neural network architecture is adopted to output the left ventricle segmentation mask and the key point position information at the same time, the error propagation problem caused by series connection of multiple models is avoided, and the accuracy and efficiency of obtaining the ejection fraction corresponding to the echocardiogram are improved.

The invention discloses an electrocardiogram-based cardiac function parameter prediction method and device, and the method comprises the steps: obtaining real-time electrocardiogram data of a target patient, inputting the real-time electrocardiogram data into a pre-trained parameter prediction model, and obtaining a parameter prediction result outputted by the parameter prediction model, the parameter prediction result at least comprises a left ventricular ejection fraction prediction result; wherein the parameter prediction model is obtained by training a pre-constructed neural network by using a sample data set, and the sample data set is constructed by using preprocessed electrocardiogram data and a corresponding classification label. By predicting the ejection fraction of the left ventricle from the electrocardiogram, the application of the electrocardiogram to the function of dynamically monitoring cardiac function parameters in real time is expanded, and the problem that in the prior art, central function parameter monitoring depends on high-end image equipment is solved; a low-cost and high-efficiency technical scheme is provided for early computer-aided diagnosis and real-time dynamic monitoring of cardiovascular diseases.

The invention discloses targeted selenium-coupled anti-inflammatory fusion protein and application thereof in acute coronary syndrome reperfusion injury repair, and belongs to the technical field of biomedicine. A GPIb-Annexin A1 fusion protein is constructed firstly, specifically, a human GPIb active fragment serving as an N-terminal targeting element and a human Annexin A1 active fragment serving as a C-terminal anti-inflammatory element are connected in series through a (Gly4Ser) 3 flexible linker, the fusion protein sequence is shown as SEQ ID NO: 3, and the GPIb-Annexin A1 fusion protein is obtained through gene synthesis, vector construction, prokaryotic expression and Ni-NTA purification; and chelating selenomethionine serving as a selenium source with the fusion protein according to the mass ratio of 3: 1 in a phosphate buffer solution with the pH value of 7.5, and dialyzing, freezing and drying to obtain the selenium chelate. Experiments prove that the selenium chelate can significantly improve the left ventricular ejection fraction and the left ventricular shortening fraction of MI / RI mice, reduce the myocardial infarction area, inhibit the expression of TNF-alpha, IL-1beta and IL-6, and reduce the long-term myocardial collagen volume fraction, and can be used for preparing acute coronary syndrome reperfusion injury repair drugs.